Not every Valley real estate deal comes with pomp and circumstance. This huge industrial transaction involving a national ...

Discover the top 11 websites to buy GLP-1 weight loss medications online. Our expert-reviewed guide helps you find safe, ...

Hims & Hers Health (HIMS 1.43%) demonstrated once again why it's one of the most interesting growth stocks outside of the tech sector when it reported strong Q3 results. While the stock has been ...

Hims & Hers Health (HIMS) traded ~6% higher on Tuesday after the telehealth platform, with its Q3 2025 results, said it is in "active discussions" with Novo Nordisk (NVO) to sell the Danish ...

The call centered around Hims & Hers’ push beyond treatment into proactive and personalized health management. Dudum confirmed plans to launch whole-body lab testing before year-end, followed by a new ...

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Hims & Hers Health HIMS-5.13%decrease; red down pointing triangle said it is now providing menopause care, marking the company’s latest push into hormone-replacement therapies. The telehealth company ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results ...

Ryan Murphy's Netflix series Monster has received backlash in the past for inaccuracies about its subjects — but what did the show get wrong about Ed Gein's case? Season 2 faced similar backlash after ...

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.